Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring

Cytometry Part B - Clinical Cytometry

Volumn 63, Issue 1, 2005, Pages 1-9

  Langebrake, Claudia ^a   Brinkmann, Iris ^a   Teigler Schlegel, Andrea ^b   Creutzig, Ursula ^a   Griesinger, Frank ^c   Puhlmann, Ulrike ^a   Reinhardt, Dirk ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Acute myeloid leukemia; Antigen shift; Childhood; Immunophenotyping; Minimal residual disease

Indexed keywords

CD34 ANTIGEN; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BIOPSY; CANCER RELAPSE; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DISEASE ACTIVITY; EVOLUTION; FLOW CYTOMETRY; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; SCHOOL CHILD;

ACUTE DISEASE; ADOLESCENT; ANTIGENS, NEOPLASM; BONE MARROW; CHILD; CHILD, PRESCHOOL; CLONE CELLS; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INFANT; KARYOTYPING; LEUKEMIA, MYELOID; NEOPLASM, RESIDUAL; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 11844252125     PISSN: 15524949     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.b.20037     Document Type: Article

References (34)

1. Kern W, Danhauser-Riedl S, Ratei R, et al. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. Haematologica 2003;88:646-653.
2. Macedo A, Orfao A, Vidriales MB, et al. Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol 1995;70:189-194.
3. Reading CL, Estey EH, Huh YO, et al. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 1993;81:3083-3090.
4. Terstappen LW, Safford M, Konemann S, et al. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia 1992;6:70-80.
5. Biondi A, Rambaldi A. Molecular diagnosis and monitoring of acute myeloid leukemia. Leuk Res 1996;20:801-807.
6. Haas OA, Kronberger M, Mayerhofer L. Cytogenetic abnormalities associated with childhood acute myeloblastic leukemia. In: Ludwig WD, Thiel E, editors. Recent results in cancer research. Berlin: Springer; 1993. p 103-112.
7. San Miguel JF, Martinez A, Macedo A, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90:2465-2470.
8. Sievers EL, Lange BJ, Buckley JD, et al. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. J Natl Cancer Inst 1996;88:1483-1488.
9. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999;38:139-152.
10. Baer MR, Stewart CC, Dodge RK, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001;97:3574-3580.
11. Hur M, Chang YH, Lee DS, et al. Immunophenotypic and Cytogenetic changes in acute leukaemia at relapse. Clin Lab Haematol 2001;23:173-179.
12. Macedo A, San Miguel JF, Vidriales MB, et al. Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J Clin Pathol 1996;49:15-18.
13. Oelschlagel U, Nowak R, Schaub A, et al. Shift of aberrant antigen expression at relapse or at treatment failure in acute leukemia. Cytometry 2000;42:247-253.
14. Tomova A, Babusikova O. Shifts in expression of immunological cell markers in relapsed acute leukemia. Neoplasma 2001;48:164-168.
15. Chucrallah AE, Stass SA, Huh YO, et al. Adult acute lymphoblastic leukemia at relapse. Cytogenetic, immunophenotypic, and molecular changes. Cancer 1995;76:985-991.
16. Guglielmi C, Cordone I, Boecklin F, et al. Immunophenotype of adult and childhood acute lymphoblastic leukemia: changes at first relapse and clinico-prognostic implications. Leukemia 1997;11:1501-1507.
17. van Wering ER, Beishuizen A, Roeffen ET, et al. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. Leukemia 1995;9:1523-1533.
18. Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol 2001;19:2705-2713.
19. Creutzig U, Reinhardt D, Zimmermann M. Prognostic relevance of risk groups in the pediatric AML-BFM trials 93 and 98. Ann Hematol 2004;83(suppl 1):S112-S116.
20. Reinhardt D, Langebrake C, Creutzig U, et al. Minimal residual disease in acute myeloid leukemia in children-standardization and evaluation of immunophenotyping in the AML-BFM-98 study. Klin Padiatr 2002;214:179-187.
21. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783-1786.
22. Ritterbach J, Harbott J, Ritter J, Lampert F. Chromosomal aberrations in childhood acute nonlymphoblastic leukemia. Haematol Blood Transfus 1990;33:153-156.
23. International System for Human Cytogenetic Nomenclature. An international system for human cytogenetic nomenclature. Basel: S Karger; 1995.
24. Harbott J, Viehmann S, Borkhardt A, et al. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 1997;90:4933-4937.
25. Hrusak O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002;16:1233-1258.
26. San Miguel JF, Vidriales MB, Lopez-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98:1746-1751.
27. Sievers EL, Lange BJ, Alonzo TA, et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003;101:3398-3406.
28. Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003;123:243-252.
29. Estey E, Keating MJ, Pierce S, Stass S. Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia. Leukemia 1995;9:972-976.
30. Kern W, Haferlach T, Schnittger S, et al. Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy. Leukemia 2002; 16:2084-2091.
31. Viehmann S, Teigler-Schlegel A, Bruch J, et al. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ ETO rearrangement. Leukemia 2003;17:1130-1136.
32. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995;85:1416-1434.
33. Thomas X, Campos L, Archimbaud E, et al. Surface marker expression in acute myeloid leukaemia at first relapse. Br J Haematol 1992;81:40-44.
34. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737.